Pharmaceutical & Life Sciences News

Pharma Executive Convicted for Promoting Off-Label Uses Seeks New Trial

May 25, 2017, 4:00 AM

A pharmaceutical company founder’s conviction should be overturned as an appellate panel said evidence not introduced could have changed the outcome, an attorney told the U.S. Court of Appeals for the Ninth Circuit (United States v. Harkonen, 9th Cir. App., 15-16844, oral arguments 5/15/17).

The May 15 oral argument is the latest appeal W. Scott Harkonen filed to overturn his wire fraud conviction in connection with a 2002 news release promoting off-label uses for Actimmune. The Food and Drug Administration approved the drug to treat rare disorders in children that also showed unapproved promise for a fatal...

To read the full article log in. To learn more about a subscription click here.